ArticleHaematologica2015

A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy.

Gautam Borthakur et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.